title: Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients.
abstract: The current study aimed to investigate the midterm (24 hour) response of 17-hydroxyprogesterone (17-OHP) and dehydroepiandrosterone sulphate (DHEA-S) to synthetic high-dose adrenocorticotropin (ACTH) in adrenal incidentalomas (Al). Seventeen patients with Al and 40 age- and sex-matched controls received synthetic ACTH (tetracosactide, 1000 microg, IM). Plasma, 17-OHP and DHEA-S were collected in basal conditions and after 1, 4, 6, 8 and 24 hours. (HPA) axis was also evaluated using circadian serum cortisol, urinary free cortisol and over-night 2 mg dexamethasone suppression. Basal plasma 17-OHP levels did not differ among the groups. However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls. Stimulated 17OH-P levels never reached 9.1 ng/ml in controls. Sixty-five (11/17) % of the patients were found to have exaggerated response. Three of the patients were found to have subclinical Cushing's syndrome and interestingly, two augmented their 17-OHP response to ACTH after unilateral adrenalectomy and normalisation of their HPA axis. Basal DHEA-S levels of the patients were significantly lower [99.21 +/- 45, 230.18 +/- 34 microg/dl, p < 0.01] and stayed persistently lower than that of the controls. Evidence of a heterozygous 21 hydroxylase deficiency, as indicated by the exaggerated 17-OHP response to ACTH, has been widely reported in Al patients. However, to our knowledge to date there is no report on augmented 17-OHP response to ACTH after adrenalectomy. Possible reasons for the augmentation were discussed.
authors: Department of Endocrinology and Metabolism, Ankara University, Medical Faculty, Turkey.
authors: Nuri
authors: N
authors: Kamel
authors: Murat Faik
authors: MF
authors: Erdoğan
authors: Vedia
authors: V
authors: Tonyukuk
authors: Sen Dağci
authors: SD
authors: Ilgin
authors: Gürbüz
authors: G
authors: Erdoğan
mesh_terms: D019326:17-alpha-Hydroxyprogesterone / Q000097:blood / Q000378:metabolism*; D000310:Adrenal Gland Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000601:surgery; D000315:Adrenalectomy; D000324:Adrenocorticotropic Hormone / Q000493:pharmacokinetics / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D019540:Area Under Curve; D016022:Case-Control Studies; D002395:Catecholamines / Q000652:urine; D002940:Circadian Rhythm; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood / Q000378:metabolism; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood / Q000652:urine; D008297:Male; D008875:Middle Aged; D018709:Statistics, Nonparametric; D014642:Vanilmandelic Acid / Q000652:urine
chemical_list: D002395:Catecholamines; D014642:Vanilmandelic Acid; D019314:Dehydroepiandrosterone Sulfate; D019326:17-alpha-Hydroxyprogesterone; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone